Free Trial
→ Forget NVDA. Put $1,000 into this stock now (From Chaikin Analytics) (Ad)tc pixel

KindlyMD (NASDAQ:NAKA) Trading Down 5.8% - Here's What Happened

Written by MarketBeat
Updated August 30, 2025
KindlyMD logo with Medical background

Key Points

  • KindlyMD, Inc. shares fell by 5.8% on Monday, trading as low as $9.35 and closing at $9.54.
  • The company reported a negative EPS of ($0.34) for the quarter, along with a negative return on equity of 131.09% and a negative net margin of 244.00%.
  • KindlyMD focuses on holistic pain management and aims to tackle the opioid epidemic by integrating prescription medicine and behavioral health services.
  • MarketBeat previews the top five stocks to own by October 1st.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) dropped 5.8% during trading on Monday . The company traded as low as $9.35 and last traded at $9.54. Approximately 211,389 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 3,010,060 shares. The stock had previously closed at $10.13.

KindlyMD Price Performance

The company has a market cap of $2.05 billion, a price-to-earnings ratio of -6.33 and a beta of 34.35. The business has a 50 day moving average price of $11.05.

KindlyMD (NASDAQ:NAKA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.34) EPS for the quarter. The company had revenue of $0.41 million during the quarter. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.

About KindlyMD

(Get Free Report)

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.

Further Reading

Should You Invest $1,000 in KindlyMD Right Now?

Before you consider KindlyMD, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KindlyMD wasn't on the list.

While KindlyMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.